NCT06313008View on ClinicalTrials.gov

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 10, 2024

Conditions
Coronary Artery DiseaseType 2 Diabetes
Interventions
DRUG

Empagliflozin 10 MG

eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).

DRUG

Vildagliptin 50 MG

eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).

Trial Locations (1)

31527

Rehab Hussein Werida, Damanhūr

All Listed Sponsors
collaborator

Tanta University

OTHER

lead

Damanhour University

OTHER

NCT06313008 - Empagliflozin Versus Vildagliptin in CAD Patients With T2DM | Biotech Hunter | Biotech Hunter